DBV TECHNOLOGIE/S (DBVT) Expected to Post Earnings of -$0.68 Per Share
Equities research analysts predict that DBV TECHNOLOGIE/S (NASDAQ:DBVT) will report earnings per share of ($0.68) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for DBV TECHNOLOGIE/S’s earnings. The company is expected to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that DBV TECHNOLOGIE/S will report full-year earnings of ($2.55) per share for the current fiscal year, with EPS estimates ranging from ($3.33) to ($2.01). For the next year, analysts expect that the company will report earnings of ($2.10) per share, with EPS estimates ranging from ($2.76) to ($1.40). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow DBV TECHNOLOGIE/S.
A number of research firms have commented on DBVT. JMP Securities restated a “buy” rating and set a $20.00 price target on shares of DBV TECHNOLOGIE/S in a research report on Wednesday, March 6th. Zacks Investment Research upgraded shares of DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Wednesday, April 10th. BidaskClub upgraded shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research report on Friday, April 5th. Finally, Stifel Nicolaus restated a “hold” rating and set a $10.00 price target on shares of DBV TECHNOLOGIE/S in a research report on Wednesday, March 6th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $14.91.
Shares of DBVT stock traded down $0.22 during midday trading on Tuesday, reaching $9.19. 157,207 shares of the company were exchanged, compared to its average volume of 169,795. DBV TECHNOLOGIE/S has a 12 month low of $3.60 and a 12 month high of $25.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Article: How to interpret the current ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.